An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer.
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Uprosertib (Primary)
- Indications Gastric cancer; Oesophageal cancer; Ovarian cancer; Uterine cancer
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 27 Jan 2012 Actual patients number is 9 as reported by ClinicalTrials.gov.
- 27 Jan 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 27 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.